EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer

Yang Zhao, Zhixia Bai, Tao Li

Translational Oncology · 2026-12 · 74 · 103068

DOI: 10.1016/j.tranon.2026.103068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2026-12. Verfasst von Yang Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Ningxia, National Natural Science Foundation of China, Natural Science Foundation of Ningxia Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antibody-drug conjugate (ADC) activity and target-dependent on-target/off-tumor toxicity depends in part on which cells express the target antigen, a feature that bulk assays cannot resolve. METHODS: We analyzed a publicly available whole-transcriptome CosMx breast tumor dataset including 154,816 cells and 18,934 genes. Eleven clinically relevant ADC targets were profiled across seven annotated lineages. Findings were contextualized using TCGA-BRCA bulk transcriptomes (1,097 tumors and 114 normal tissues) and assessed in two public Xenium breast cancer specimens. RESULTS: HER2 (ERBB2), TROP2 (TACSTD2), HER3 (ERBB3), NECTIN4 and MUC1 were enriched in tumor epithelium. B7-H3 (CD276) was highest in endothelial and myoepithelial cells, with similar mean expression in stromal and tumor cells. PSMA (FOLH1) was enriched in endothelium. TCGA-BRCA tumor-normal differences did not identify these cellular sources. No overall-survival association remained after multiple-testing correction or covariate adjustment. HER2 and TROP2 tumor enrichment recurred in both Xenium specimens, whereas EGFR was not tumor restricted. CONCLUSIONS: Cell-resolved spatial profiling separated ADC targets enriched in tumor epithelium from those expressed in vascular and stromal compartments. B7-H3 and PSMA localization was consistent with prior immunohistochemical reports and is confirmatory. These RNA-level results do not establish surface-protein abundance, ADC response, or clinical toxicity. Low-abundance microenvironmental findings remain based on a single discovery specimen and require protein-level validation. Protein-level confirmation, and correlation with ADC efficacy and toxicity, are required before these maps can inform clinical decisions.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugateBreast cancerHER2Single-cell analysisSpatial transcriptomicsTROP2Tumor microenvironment

Autor:innen und Institutionen

  • Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
  • Department of Anesthesiology and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
  • Department of Gastrointestinal Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China. Electronic address: litao2151@yeah.net.

Förderung

  • Key Research and Development Program of Ningxia
  • National Natural Science Foundation of China
  • Natural Science Foundation of Ningxia Province

Zitieren

APA

Zhao, Y., Bai, Z., & Li, T. (2026). Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer. Translational Oncology, 74, 103068. https://doi.org/10.1016/j.tranon.2026.103068

Vancouver

Zhao Y, Bai Z, Li T. Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer. Translational Oncology. 2026;74:103068. doi:10.1016/j.tranon.2026.103068

BibTeX
@article{Zhao2026,
  author = {Zhao, Yang and Bai, Zhixia and Li, Tao},
  title = {Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer},
  journal = {Translational Oncology},
  year = {2026},
  volume = {74},
  pages = {103068},
  doi = {10.1016/j.tranon.2026.103068}
}
Kostenlos starten →